Dembrowski Gerald C, Barnes Jessica W
20Lighter, LLC Cheyenne, Wyoming, 82007, USA.
20Lighter, LLC Cheyenne, Wyoming, 82007, USA.
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1001-1004. doi: 10.1016/j.dsx.2020.05.036. Epub 2020 Jun 16.
Metabolic syndrome (MetS), defined as a cluster of metabolic abnormalities including visceral adiposity, insulin resistance, hypertension, and dyslipidemia, now affects more than a third of adults in the United States highlighting the need for effective complementary approaches to current treatments.
We present a case report of a 47-year-old man with a history of MetS and poorly controlled Type 2 Diabetes Mellitus (T2D) who completed a 20Lighter program (20L) including a very low calorie diet (VLCD). At the time of enrollment his BMI was 32.7, HbA1c was 9.6%, and prescription medication history included lisinopril, lovastatin, and metformin, glimepiride, and combination sitagliptin/metformin.
Fifteen weeks after beginning 20L (6 weeks after program completion) marked reduction of weight, visceral adipose tissue and normalization of HbA1C was seen, and all medications were withdrawn.
While longer follow-up is required, this case report shows that a comprehensive program including a relatively short period of nutritionally complete VLCD, followed by gradual return to moderate dietary lifestyle is capable of producing clinically significant improvements in health and quality of life in individuals with MetS and poorly controlled T2D.
代谢综合征（MetS）被定义为一组代谢异常，包括内脏肥胖、胰岛素抵抗、高血压和血脂异常，目前影响着美国超过三分之一的成年人，这凸显了对当前治疗方法采用有效补充措施的必要性。
我们报告了一例47岁男性病例，他有代谢综合征病史且2型糖尿病（T2D）控制不佳，该患者完成了一个20Lighter计划（20L），包括极低热量饮食（VLCD）。入组时，他的体重指数（BMI）为32.7，糖化血红蛋白（HbA1c）为9.6%，处方药用药史包括赖诺普利、洛伐他汀、二甲双胍、格列美脲以及西格列汀/二甲双胍复方制剂。
开始20L计划15周后（计划完成6周后），体重、内脏脂肪组织明显减少，HbA1C恢复正常，所有药物均停用。
虽然需要更长时间的随访，但该病例报告表明，一个综合计划，包括一段相对较短的营养全面的极低热量饮食期，随后逐渐恢复到适度的饮食生活方式，能够使患有代谢综合征和控制不佳的2型糖尿病的个体在健康和生活质量方面取得临床上显著的改善。
